Adela将在 2025年 ASCO年会上展示其组织不可知性 MRD检测和反应监测测试的能力，以预测实体瘤进展并识别对免疫治疗无反应的患者-动脉网

Adela to Present Data Highlighting Ability of its Tissue-Agnostic Test for MRD Detection and Response Monitoring to Predict Progression and Identify Non-Responders to Immunotherapy in Solid Tumors at the 2025 ASCO Annual Meeting

CISION 等信源发布 2025-05-30 21:00



可切换为仅中文







FOSTER CITY, Calif.

福斯特城，加利福尼亚州

，

May 30, 2025

2025年5月30日

/PRNewswire/ -- Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary genome-wide methylome enrichment technology, is presenting results of two studies demonstrating the ability of its MRD test to predict progression and identify non-responders to immunotherapy at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from .

/PRNewswire/ -- Adela, Inc.是一家通过专有的全基因组甲基化富集技术在分子残留病（MRD）监测和早期癌症检测领域的血液测试创新者，将在2025年美国临床肿瘤学会（ASCO）年会上展示两项研究的结果，这些研究表明其MRD测试能够预测疾病进展并识别对免疫治疗无反应的患者。

May 30

5月30日

–

June 3, 2025

2025年6月3日

。

'In patients with advanced cancer receiving immunotherapy, it can be challenging to differentiate true progression from pseudoprogression during early treatment cycles based on imaging,' said

“在晚期癌症患者接受免疫治疗时，根据影像学检查，在早期治疗周期中很难区分真实进展和假性进展，”

Lillian Siu

李莲·萧

, MD, FRCPC, Medical Oncologist and Senior Scientist, Princess Margaret Cancer Centre, University Health Network. 'To better identify non-responders and guide timely treatment adjustments, more reliable response assessment tools are needed. Methylation-based circulating tumor DNA (ctDNA) technology shows promise in these regards.'.

医学博士，FRCPC，医学肿瘤学家及资深科学家，玛格丽特公主癌症中心，大学健康网络。“为了更好地识别无反应者并指导及时的治疗调整，我们需要更可靠的反应评估工具。基于甲基化的循环肿瘤DNA（ctDNA）技术在这些方面显示出潜力。”

The ability of Adela's test to identify progression in patients treated with immunotherapy was demonstrated in two studies. The first study included banked samples from 64 patients with advanced head & neck, breast, ovarian, melanoma, or other solid tumors who received pembrolizumab. Blood samples were collected pre-treatment and prior to initiation of cycle 3 of treatment.

两项研究证明了Adela的测试在识别接受免疫治疗的患者中的疾病进展的能力。第一项研究包括64名接受派姆单抗治疗的晚期头颈癌、乳腺癌、卵巢癌、黑色素瘤或其他实体肿瘤患者的存档样本。在治疗前和第三周期治疗开始前采集了血液样本。

A decrease in ctDNA from the pre-treatment blood draw to the pre-cycle 3 blood draw was associated with a significantly better PFS [hazard ratio (HR) of 0.28 (0.15, 0.49); p<0.0001] and OS [HR 0.42 (0.24, 0.76); p=0.003]..

从治疗前采血到第3周期前采血，ctDNA的减少与显著更好的无进展生存期（PFS）[风险比（HR）为0.28（0.15, 0.49）；p<0.0001]和总生存期（OS）[HR 0.42（0.24, 0.76）；p=0.003]相关。

'These results show promise in assessing response to immunotherapy early in a patient's course of treatment,' said

“这些结果表明，在患者治疗过程的早期评估对免疫疗法的反应方面展现出希望，”

Enrique Sanz-Garcia

恩里克·桑兹-加西亚

, MD, Medical Oncologist and Clinician-Investigator at Princess Margaret Cancer Centre, University Health Network. 'Identifying non-response earlier can support timely treatment decisions and help avoid unnecessary toxicity.'

，医学博士，玛格丽特公主癌症中心（大学健康网络）的医学肿瘤学家和临床研究员。“及早识别无反应者可以支持及时的治疗决策，并有助于避免不必要的毒性。”

The second study included banked samples from 63 patients with stage III/IV non-small cell lung cancer treated with definitive chemoradiation followed by consolidative durvalumab (stage III) or with PD-1 inhibitors +/- chemotherapy (stage IV). Blood samples were collected pre-treatment, 2-4 weeks after treatment initiation and approximately 6-8 weeks thereafter until progression.

第二项研究包括来自63名接受确定性化疗放疗后使用度伐利尤单抗（III期）或PD-1抑制剂 +/- 化疗（IV期）的III/IV期非小细胞肺癌患者的储存样本。在治疗前、治疗开始后2-4周以及此后约6-8周直至病情进展期间采集了血液样本。

Patients with a positive MRD test showed significantly worse PFS than those who tested negative (HR 4.8; 95% CI, 2.1-10.8; P < 0.0001)..

MRD检测呈阳性的患者显示出比检测呈阴性患者的PFS显著更差（HR 4.8；95% CI，2.1-10.8；P < 0.0001）。

'Together, these two studies demonstrate the potential of Adela's tissue-agnostic test to predict outcomes and support clinical decision-making for patients receiving immunotherapy across a range of cancer types,' said Dr.

“这两项研究共同证明了Adela的组织不可知测试在预测结果和支持跨多种癌症类型接受免疫治疗患者的临床决策方面的潜力，”博士说道。

Anne-Renee Hartman

安妮-雷内·哈特曼

, Chief Medical Officer at Adela. 'Because tumor tissue is often unavailable in patients with advanced cancer, Adela's blood-only, tissue-free approach offers a universally accessible solution for this population.'

阿德拉公司的首席医疗官表示：“由于晚期癌症患者通常无法获取肿瘤组织，阿德拉的仅血液、无组织的方法为这一群体提供了一个普遍可及的解决方案。”

Adela's MRD test based on its genome-wide methylome enrichment platform is currently available to biopharmaceutical companies and other investigators for Research Use Only (RUO), including for biomarker discovery and drug development. Adela plans to commercialize the test in 2025 for use in patients who have received curative intent treatment for head & neck cancer, regardless of HPV status, to detect recurrence earlier and help guide treatment decision-making..

基于其全基因组甲基化富集平台的Adela MRD测试目前已可供生物制药公司和其他研究人员用于研究用途（RUO），包括生物标志物发现和药物开发。Adela计划在2025年将该测试商业化，用于接受过头颈癌治愈性治疗的患者，无论HPV状态如何，以更早检测复发并帮助指导治疗决策。

Presentation Details

演示详情

Abstract #8550

摘要 #8550

: Identification of immunotherapy early treatment failure in non-small cell lung cancer (NSCLC) using a novel cell-free DNA (cfDNA) tissue-agnostic genome-wide methylome enrichment assay

利用新型无细胞DNA（cfDNA）组织不可知全基因组甲基化富集检测鉴定非小细胞肺癌（NSCLC）免疫治疗早期失败

Dr.

博士

Tuan Hoang

黄先生

Hall A, Poster Board: 30

大厅A，海报板：30

Saturday May 31, 2025

2025年5月31日，星期六

1:30 PM-4:30 PM CDT

下午1:30 - 下午4:30 中央夏令时间

Abstract # 2545

摘要 # 2545

: Validation of an optimized tissue-agnostic genome-wide methylome enrichment assay to predict clinical outcomes in patients treated with pembrolizumab

: 验证一种优化的组织无关的全基因组甲基化富集分析方法，以预测接受派姆单抗治疗患者的临床结果

DR.

博士

Enrique Sanz-Garcia

恩里克·桑兹-加西亚

Hall A, Poster Board: 192

A厅，海报板：192

Monday June 2, 2025

2025年6月2日，星期一

1:30 PM-4:30 PM CDT

下午1:30 - 下午4:30 中央夏令时间

About Adela

关于阿德拉

Adela is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Adela's blood-based, tissue-free product ensures universal accessibility to MRD testing for patients with cancer, eliminating any dependency on tumor tissue availability.

阿德拉正在开发一流的技术，通过血液检测来加速癌症的诊断并改善癌症管理，这些检测可用于微小残留病（MRD）监测和多癌种早期检测（MCED）。阿德拉基于血液、无组织依赖的产品确保了癌症患者对MRD检测的普遍可及性，消除了对肿瘤组织可用性的依赖。

Adela's approach efficiently captures extensive, biologically-relevant genomic information from the methylome, providing greater opportunity to detect cancer signals in the blood compared to platforms that target a smaller set of genomic regions. Adela's first product utilizing this genome-wide methylome enrichment platform was recently clinically validated for predicting and surveilling for recurrence in patients with head & neck cancer and published in .

阿德拉的方法能够有效地从甲基化组中捕获广泛且与生物学相关的基因组信息，相比那些针对较小基因组区域的平台，这种方法提供了更大的机会来检测血液中的癌症信号。阿德拉利用这一全基因组甲基化组富集平台的首款产品最近在头颈癌患者的复发预测和监测方面进行了临床验证，并已发表。

Annals of Oncology

肿瘤学年鉴

. Adela's investors are F-Prime Capital, OrbiMed, Deerfield Management, Decheng Capital, RA Capital Management and Labcorp. Find more information at

Adela的投资者包括F-Prime Capital、OrbiMed、Deerfield Management、Decheng Capital、RA Capital Management和Labcorp。更多信息请访问

adelabio.com

。

Princess Margaret Cancer Centre, University Health Network,

玛格丽特公主癌症中心，大学健康网络，

Toronto, Canada

加拿大多伦多

SOURCE Adela